Medtide Inc.

泰德醫藥(浙江)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3880)

CHANGE OF JOINT COMPANY SECRETARY, AUTHORISED REPRESENTATIVE AND PROCESS AGENT; AND WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES

The board (the "**Board**") of directors (the "**Director(s)**") of Medtide Inc. (the "**Company**") hereby announces that Mr. Lee Chung Shing ("**Mr. Lee**") has tendered his resignation as (i) the joint company secretary of the Company ("**Joint Company Secretary**"); (ii) an authorised representative of the Company (the "**Authorised Representative**") for the purpose of Rule 3.05 of the Rules Governing the Listing of Securities (the "**Listing Rules**") on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**"); and (iii) the representative for acceptance of service of process and notices on behalf of the Company in Hong Kong as required under Rule 19A.13(2) of the Listing Rules and Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) (the "**Process Agent**") with effective from September 26, 2025.

Mr. Lee has confirmed that he has no disagreement with the Board and there are no matters that need to be brought to the attention of the shareholders of the Company or the Stock Exchange in relation to his resignation.

The Board further announces that, following the resignation of Mr. Lee, Mr. Ng Tung Ching Raphael ("**Mr. Ng**") has been appointed as the Joint Company Secretary, the Authorised Representative and the Process Agent with effective from September 26, 2025. Ms. Li Lingmei ("**Ms. Li**") will continue to act as the other Joint Company Secretary.

The biographical details of Mr. Ng and Ms. Li are as follows:

Mr. Ng

Mr. Ng is a seasoned professional with over 15 years of extensive experience in the legal and company secretarial domains, specializing in corporate governance and compliance. He currently serves as the Assistant Vice President, Entity Solutions of Computershare Hong Kong Investor Services Limited.

Mr. Ng holds a Master's Degree in Chinese Business Law from The Chinese University of Hong Kong and a Master's Degree in Professional Accounting and Corporate Governance from The City University of Hong Kong. He earned his Bachelor's Degree in Law from Manchester Metropolitan University. Mr. Ng is an Associate Member of both The Hong Kong Chartered Governance Institute ("**HKCGI**") and The Chartered Governance Institute in the United Kingdom. He also possesses the practitioner's endorsement from HKCGI.

Ms. Li

Ms. Li is our executive Director, joint company secretary and the secretary to the Board. Ms. Li has been appointed as our executive Director since May 2024. Ms. Li joined our Group in September 2023 as the secretary to the Board.

Prior to joining our Group, from February 2023 to September 2023, she was an industry expert at Firstred Capital (晨壹投資), which is primarily engaged in buy & build opportunities with a focus on new economy industries including industrial & technology, healthcare, and consumer sectors. From September 2018 to November 2022, she worked at ICLEGEND MICRO group, and was the vice president of sales and marketing of ICLEGEND MICRO (Nanjing) Co., Ltd. (南京矽典微系統有限公司), which is focused on advancing wireless technology through innovative products and solutions, from August 2019 to November 2022. From November 2016 to July 2018, she worked as a sales director at Nexperia (China) Co., Ltd, a company known for essential components used in a wide range of electronic designs globally.

Ms. Li graduated from Southeast University (東南大學) in the PRC in June 1999, majoring in computer science. She obtained a finance master's degree in business administration from Cheung Kong Graduate School of Business (長江商學院) in the PRC in September 2013. Additionally, Ms. Li obtained an MBA degree from IMD Business School and an EMBA degree Cheung Kong Graduate School of Business (長江商學院) in the PRC both in September 2016. She obtained the Fund Practitioner Qualification from the Asset Management Association of China (中國證券投資基金業協會) in May 2019.

WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES

References is made to the waiver (the "**Original Waiver**") granted to the Company by the Stock Exchange from strict compliance with the requirements under Rules 3.28 and 8.17 of the Listing Rules in relation to the eligibility of Ms. Li to act as a Joint Company Secretary for a three-year period commencing from the date on which the H shares of the Company are listed on the Stock Exchange and from which dealings in the shares are permitted to commence on the Stock Exchange (i.e. June 30, 2025) (the "**Original Waiver Period**"), on the condition that Ms. Li must be assisted by Mr. Lee as a Joint Company Secretary during the Original Waiver Period to enable her to acquire relevant experience (as defined in Note 2 to Rule 3.28 of the Listing Rules), in order to discharge her duties under the position of a Joint Company Secretary. Relevant details of the Original Waiver was disclosed in the prospectus of the Company dated June 20, 2025.

The Company has applied to the Stock Exchange for, and the Stock Exchange has granted, a new waiver from strict compliance with the requirements under Rules 3.28 and 8.17 of the Listing Rules with respect to the eligibility of Ms. Li to act as a Joint Company Secretary (the "**New Waiver**") from September 26, 2025 (i.e. from the effective date of Mr. Ng's appointment as the Joint Company Secretary) to June 29, 2028 (i.e. the end of the Original Waiver Period) (the "**Remaining Waiver Period**"). The New Waiver is granted on the following conditions:

i. Ms. Li must be assisted by Mr. Ng during the Remaining Wavier Period; and

ii. the New Waiver could be revoked if there are material breaches of the Listing Rules by the Company.

Before the end of the Remaining Waiver Period, the Company must demonstrate and seek confirmation from the Stock Exchange that Ms. Li, having had the benefit of Mr. Lee and Mr. Ng's assistance for approximately three years, has attained the relevant experience and is capable of discharging the functions of a company secretary under Rule 3.28 of the Listing Rules such that a further waiver will not be necessary. The Stock Exchange may withdraw or change the New Waiver if the Company's situation changes.

The Board would like to take this opportunity to express its sincere gratitude to Mr. Lee for his valuable contribution and services to the Company during his tenure of office, and welcome Mr. Ng to his new appointment.

By order of the Board
Medtide Inc.
Dr. Xu Qi
Chairwoman and chief executive officer

Hong Kong, September 26, 2025

As at the date of this announcement, the executive Directors of the Company are Dr. Xu Qi (徐琪), Dr. Li Xiang (李湘), Ms. Li Xiangli (李湘莉), Ms. Cheng Tao and Ms. Li Lingmei (李玲梅); the non-executive Director of the Company is Mr. Wu Yihui (吳一暉); and the independent non-executive Directors of the Company are Dr. Yu Cheung Hoi (于常海), Dr. Zhu Xun (朱迅) and Mr. Xia Xinsheng (夏心晟).